Background--Despite concerns about mineralocorticoid receptor antagonist therapies (MRAs) underuse and misuse in patients with heart failure, temporal and institutional variations of MRA prescription have not been reported.
I
n 2011, experts estimated that 68 000 lives could be saved per year in the United States with optimal implementation of evidence-based therapies in patients with heart failure with left ventricular reduced ejection fraction (HFrEF). 1 Of 6 therapies, implementation of mineralocorticoid receptor antagonist therapy (MRA) was estimated to result in nearly a third of this potential benefit of improved care. Furthermore, 3 randomized trials have found MRAs to be a highly efficacious therapy with a low number needed to treat to save 1 life (number needed to treat to save 1 life for 1 year 18).
2,3
Unfortunately, only one third of eligible HF patients actually receive an MRA prescription at hospital discharge 4 or in the outpatient setting, 5 perhaps because MRAs have the capacity to induce potentially life-threatening consequences by causing hyperkalemia. Furthermore, risk factors for hyperkalemia (eg, chronic kidney disease, elevated serum potassium level, potassium supplementation) are common in patients with HF, thus creating a need to balance use in ideal candidates with avoidance of use in those who are at risk for adverse consequences of therapy. Alongside the evidence of underuse, other studies have documented high rates of use (up to 1 in 6 patients) in non-ideal patients who are at high risk 6 for hyperkalemia. Despite knowledge of underuse of MRA therapy, temporal trends in MRA use and variation of MRA prescribing between institutions are not well described. The assessment of temporal trends is important to understand the effectiveness of past and current efforts in narrowing the treatment gap for evidence-based MRA use 2, 3, 7 and therefore inform future resource allocation. Understanding institutional-level variation is important for the design of quality improvement interventions and identification of best practices. For example, homogeneous underuse would signify that a physician-level educational campaign is required to improve optimal MRA use, while heterogeneity in MRA prescription will indicate the need to evaluate local barriers and facilitators and possibly modeling best practices to narrow the MRA treatment gap. The aim of this study was to characterize temporal trends and hospital variation in MRA prescription for ideal and non-ideal candidates in a nationwide cohort of veterans with HFrEF after HF hospitalization.
Methods Human Subjects Protection
This study was approved by the Providence VA Medical Center Institutional Review Board with a waiver of informed consent. Centers for Medicare and Medicaid Services data were provided with permission from Veterans Health Administration Medicare and Medicaid Analysis Center.
Data Sources
The VA External Peer Review Program is a nationwide inpatient and outpatient random sample of veterans with at least 2 years of continuous enrollment who are evaluated for evidence-based performance measures. 
Outcomes Measures and Definitions
The primary outcome measure was prescription (≥14 pills) of an MRA within 90 days of hospital discharge in Ideal and NonIdeal candidates. Because VA hospitals typically fill new patient prescriptions prior to hospital discharge, we included any inpatient prescriptions (≥14 pills) within 48 hours preceding discharge. A 14-pill count was chosen because it represented a minimum 2-week supply. All discharge medications were determined in the same manner. The 90-day period was chosen because this period reflects the treatment strategy after HF hospitalization. Furthermore, a prior study found that some MRA-eligible patients who were not prescribed an MRA at discharge subsequently filled a prescription within 90 days. 
Statistical Analysis

Patient-level analyses
We calculated the proportions of patients who received an MRA prescription within 90 days of discharge in the Ideal and Contraindication cohorts. We then applied the CochranArmitage trend test to assess temporal trends across the study period (FY2003-2009). Next, we assessed the correlates of MRA use in the Ideal cohort by comparing patient demographics, vital signs, medications, lab values, and existing comorbidities among veterans who received a MRA prescription within 90 days of discharge compared to those who did not, using v 2 tests for categorical covariates and 1-way ANOVAs for continuous variables. We included noncompliance (ICD-9 v15.81) with medical treatment as a covariate for exploratory purposes. This was not intended to be a surrogate for patients who would not be expected to comply with MRA prescription, since a provider's assessment of patient's capacity for medication adherence cannot be assessed by administrative code alone. We utilized logistic regression with MRA prescription at discharge as the dependent variable and a backward selection procedure was used for covariate selection with a criterion of P<0.10 for model entry and termination. To determine the effects of practice variation in MRA prescription (in Ideal and Non-Ideal cohorts), we used generalized estimating equations to calculate the median odds ratio 12 (MOR). Models were adjusted for patient-level clinical and demographic characteristics as well as fiscal year to account for time trends and VA facility to account for clustering by the institution. A MOR of 1.0 suggests no meaningful variation in the odds of 2 individuals with similar characteristics receiving a MRA prescription at different, randomly selected hospitals, whereas an increase of MOR >1.0 (eg, MOR of 2.0) indicates that the odds of receiving a MRA prescription would be 2-fold higher for 2 patients with identical characteristics discharged from randomly selected hospitals. Based on previous literature, a MOR >1.2 indicates significant practicelevel variation. 13 
Hospital-level analyses
To describe institutional-level variation in MRA prescription among Ideal and Non-Ideal patients, we assessed the distributions and interquartile ranges of MRA prescription by institution. In this analysis, we excluded hospitals with <2 eligible patients per fiscal year. We then conducted a sensitivity analysis in which we excluded hospitals with <20 candidates for MRA therapy from FY2003 to 2009 to determine whether volume of eligible patients may contribute to institutional-level variation in MRA prescription practices. We then used Spearman correlation to estimate the correlation in hospital-level MRA prescription between Ideal and NonIdeal candidates. All analyses were performed using the SAS statistical package version 9.3 (Cary, NC) and approved by the Providence VAMC Institutional Review Board. Tests were 2-tailed and P<0.05 was considered statistically significant. (1) 111 (1) 74 (2) 2004, n (%) 130 (1) 92 (1) 38 (1) 2005, n (%) 2334 (17) 1552 (17) 782 (19) 2006, n (%) 3488 (26) 2434 (26) 1054 (26) 2007, n (%) 3923 (29) 2696 (29) 1227 (30) 2008, n (%) 1307 (10) 985 (11) 322 (8) 2009, n (%) 2044 (15) 1485 (16) 559 (14) Age at index date, mean (SD)
71 (11) 71 (11) 71 (11) Female, n (%) 131 (1) 88 (1) (7) 29 (7) 29 (7) Discharge lab values Sodium, mEq/L, mean (SD)
138 (5) 138 (4) 
Results
Baseline Characteristics
The characteristics of the overall, Ideal, and Non-Ideal cohorts are presented in Table 1 . For the overall cohort, only 2% had filled a MRA prescription prior to hospitalization, but >90% of patients filled prescriptions for a b-blocker or ACE inhibitor (or ARB) at discharge. Mean serum potassium at discharge was 4.1 mEq/L (SD=0.5), and serum creatinine was 1.6 mg/dL (SD=1.2). Patients had a mean of 4.8 (SD=2.6) comorbidities (defined by Elixhauser 11 ) in the prior 2 years. One in 6
patients had a history of noncompliance (ICD-9 v15.81) with medical treatment. 
Proportion and Trends in MRA Use in Ideal Candidates
Thirty-six percent (n=3408) of Ideal candidates (n=9355) were prescribed a MRA within 90 days of discharge ( (Figure 2 ). This trend persisted when restricting analysis to patients (n=8196) who received both a b-blocker and ACE inhibitor (or ARB) within 90 days of discharge (from 45% to 31%, P<0.0001). Figure 3 ). This temporal trend was consistent for all 3 subcategories of contraindicated MRA prescription: documented MRA contraindication (P=0.0013), serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women (P=0.0004), and serum potassium >5.0 mEq/L (P=0.03).
Proportion and Trends in MRA Use in Non-Ideal Candidates
Hospital-Level Variation
Among hospitals with at least 2 eligible candidates per fiscal year, the hospital-level MRA prescribing rate (n=125 hospitals) for Ideal candidates ranged from 0% to 71% (median 36% [interquartile range 28, 45]) ( Figure 4A ). The corresponding rate for Non-Ideal candidates (n=120 hospitals) ranged from 0% to 100% (median 26% [interquartile range 18, 34]) ( Figure 4B ). Sensitivity analysis restricting to hospitals with at least 20 Ideal and Non-Ideal candidates for MRA therapy, respectively, during the study period demonstrated very similar results ( Figure 5A and 5B period, respectively, the correlation was similar (r=0.39, P<0.001, Figure 6B ).
Effect of Hospital Variation on the Individual Patient: MOR of MRA Prescription in Ideal and Non-Ideal Cohorts
Univariate predictors of MRA prescription are listed in Table 2 . Compared with patients who did not receive a MRA prescription, MRA-treated patients had slightly better renal function (serum creatinine and blood urea nitrogen), but there was no difference in serum potassium between the 2 groups. Multivariable predictors of MRA prescription (P<0.05) are listed in Table 3 . Of these predictors, prescription of digoxin, lower age, lower systolic blood pressure, and presence of liver disease accounted for the greatest percentage of total variability in MRA use. Importantly, a coded diagnosis of noncompliance was not predictive of MRA prescription. After adjustment for patient predictors and clustering within hospitals, the MORs of MRA prescription for Ideal and NonIdeal candidates were 1.44 and 1.36, respectively, suggesting significant practice variation. In other words, for 2 individuals discharged from 2 randomly selected hospitals, the odds of 1 of them being prescribed with an MRA would be 44% higher (for Ideal candidates) and 36% higher (for Non-Ideal candidates) than for the other individual, despite similar characteristics and indications/contraindications for therapy.
Discussion
In a national cohort of veterans discharged for HF between 2003 and 2009, MRA prescription decreased over time. MRA prescription fell not only in Non-Ideal candidates, but unexpectedly fell in Ideal candidates. The MORs of MRA prescription for both Ideal and Non-Ideal candidates indicate significant institutional-level variation. These findings suggest that many patients who could benefit from MRAs are still not receiving them and that there is a wide gap between high-and low-performing institutions. This is to our knowledge the first study to report hospitallevel variation in MRA prescribing. The MOR for both Ideal and Non-Ideal candidates were above the threshold required to indicate significant practice-level variation, defined as MOR >1.2.
13 Indeed, the degree of variation in MRA prescription was comparable with practice-level variation in warfarin prescribing (MOR 1.3) in patients with atrial fibrillation.
13
However, the practice variation was lower when compared to variation of other performance measures such as primary However, in that study the proportion of patients who received a MRA prescription increased from 28% to 34% over the 3-year study period, in contrast to the declining trend of 41% to 31% found in our study from 2003 to 2009. This declining trend persisted in a sensitivity analysis that included only those patients treated with both b-blockers and ACE inhibitors, an approach advocated in the European Society of Cardiology Heart Failure guideline 17 when selecting patients for MRA therapy. The reasons for these contrasting temporal trends between the 2 studies could be due to different duration of comparison (7 versus 3 years) or a greater MRA utilization at VA hospitals after the Randomized Aldactone Evaluation Study trial, 3 which regressed to the national baseline over time. Another possibility is that non-VA, Get With The Guidelines hospitals benefited from participating in a quality-improvement registry that provides hospitals with performance data on their MRA utilization rates. In contrast, while VA hospitals did establish a HF Network (community of practitioners) and collect basic HF performance data (ACE/ ARB for LVEF <40%, measurement of LVEF, smoking cessation, discharge instructions), they did not participate in the Get With The Guidelines registry and did not have specific quality-improvement efforts targeting MRA utilization.
Nonetheless, the widening MRA treatment gap in the VA over time suggests opportunities for improvement and merits additional investigation. The proportion of Non-Ideal candidates (27%) who were prescribed a MRA was much higher than that found in the Get With The Guidelines study of Albert et al 4 There were several methodological considerations in our study. First, we measured MRA exposure up to 90 days after hospitalization to capture a complete picture of HF pharmacotherapy in the transition from hospital to home. This is important because renal dysfunction typically worsens during and immediately after HF hospitalization 19 and because 13%
of Medicare patients with HF who are discharged without a MRA subsequently filled a new MRA prescription within 90 days. 10 Therefore, we utilized serum potassium and creatinine values at time of hospital discharge to determine MRA eligibility rather than at admission, 4 which mirrors the process of clinical decision making. Second, we carefully excluded patients who were not ideal for MRA therapy based on an elevated serum potassium level (≥5.0 mEq/L) prior to hospital discharge as well as those with a history of serious hyperkalemia, whether diagnosed by ICD-9 code or evidence of an elevated potassium ≥6.0 mEq/L, as far back as 2 years. Incorporation of laboratory data is important because ICD-9-defined hyperkalemia underestimates the true incidence of laboratory-defined serious hyperkalemia (serum potassium ≥6.0). 20 Third, the study time period pre-dated the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure trial (2011), which expanded the indication for MRAs (ie, eplerenone) in select patients with mild HF symptoms. 7 Thus, we might not have captured the potential increase in MRA use after the publication. However, the 7-year time window of our study provides an ample window to assess the impact on clinical practice before and after a 2004 publication on MRA-related hyperkalemia. Fourth, our use of clinical and laboratory variables from electronic medical records in addition to standard administrative data may be more sensitive to identify patient-specific contextual factors 21 that would preclude use of a MRA than administrative data alone. Fifth, the VA provides a unique lens in which to examine quality of HF care. The VA is the largest integrated health system in the United States, with an electronic medical record system that allows for detailed clinical assessment of MRA indication as well as tracking of prescriptions for patients despite geographic mobility. 22 Features common to VA hospitals such as a national formulary, electronic medical record, and academic affiliations may favor a homogeneous pattern of MRA utilization. Furthermore, veterans with HF are typically older, more symptomatic, and have more comorbidities than non-VA patients yet have similar outcomes. 23 Sixth, we utilized a LVEF cutoff of <40%, rather than ≤35%, due to limitations of the VA clinical data sets, though some studies on this topic have also utilized a cutoff of LVEF <40%. There was a temporal decline in MRA prescription among Ideal candidates from 2003 to 2009 as well as important hospital-level variation in MRA use for Ideal and Non-Ideal candidates in the VA system, suggesting the importance of system factors in MRA prescribing in addition to patient factors. System efforts identifying best practices while assessing local barriers to MRA prescription will be needed to target low use of MRA in eligible patients and to reduce use in patients who could potentially be harmed.
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